Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Recommendation of “Hold” by Analysts
Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) has been given an average rating of “Hold” by the eleven analysts that are currently covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price […]
More Stories
Jeremy Jr Robinson Net Worth: How Much Does the Best-Seller Earn?
A New York Times best-selling author, Jeremy Jr Robinson, often makes headlines for the wealth he has earned. In this...
AAR (NYSE:AIR) Issues Earnings Results, Beats Estimates By $0.03 EPS
AAR (NYSE:AIR – Get Free Report) posted its earnings results on Monday. The aerospace company reported $0.85 EPS for the...
Flagship Communities Real Estate Investment Trust (MHCUF) to Issue Monthly Dividend of $0.05 on October 15th
Flagship Communities Real Estate Investment Trust (OTCMKTS:MHCUF – Get Free Report) announced a monthly dividend on Monday, September 16th, NASDAQ...
Cromwell Property Group Plans Interim Dividend of $0.01 (ASX:CMW)
Cromwell Property Group (ASX:CMW – Get Free Report) announced a interim dividend on Wednesday, September 25th, MarketIndexAU reports. Shareholders of...
Look to Tech for Dividends
By Anne Kates Smith, Kiplinger’s Personal Finance, distributed by Tribune News Service Investors searching for dividends rarely look among the...
Understand Chronic Inflammation and 6 Ways To Reduce It
By Emma Suttie, D. Ac., AP Chronic inflammation is like a silent intruder within your body—quietly stoking the embers of...